Promis Dx Presents Validation Data for Urine DNA Test for Bladder Cancer Detection in Hematuria
Pasadena, California, September 10, 2021
Promis Diagnostics Inc. recently presented clinical validation data for CystoChek, its proprietary urine-based DNA methylation test of PENK for bladder cancer (BCa) detection in hematuria, at the 2021 American Urological Association (AUA) Annual Meeting.
Researchers from Genomictree Inc., Chungnam National University Hospital (Daejeon, South Korea), and Promis previously discovered that aberrant methylation of PENK, a potential biomarker, frequently occurs in bladder cancer. Two separate clinical studies were conducted to further demonstrate their discovery’s validity and evaluate the performance of CystoChek. First, in a retrospective study, the data showed a sensitivity of 91.0% with a specificity of 93.5% in detecting Ta high-grade and greater stages of BCa in 567 hematuria patients. Second, in a prospective study, the data demonstrated a sensitivity of 93.2% with a specificity of 90.4% in detecting all of Ta high-grade and greater stages of BCa in 183 hematuria patients who then received cystoscopy procedures.
“CystoChek is an accurate and cost-effective bladder cancer detection tool that we hope to present to the community with no delay. The sensitivity of the urine DNA test for early detection of bladder cancer will provide significant benefits not only to the patients but also to healthcare stakeholders,” said Sungwhan An, CEO of Promis.
Promis Diagnostics Inc. Prepares for a Poster at AUA Annual Meeting
Pasadena, California, August 27, 2021
Promis Diagnostics Inc. announced that it is preparing for a poster presentation at American Urological Association (AUA) Annual Meeting. As the meeting has gone entirely virtual due to Covid-19, the poster presentations will be available online for participating attendees. AUA Annual Meeting is held from September 10 to 13, and you can register at www.aua2021.org.